Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To be included, patients must have diagnosis of Spasticity by IC10 criteria.~* We will enroll patients on current treatment for spasticity at the Spasticity outpatient clinic of HCPA, already in treatment with BTA or starting that treatment based on their doctors' decision, who are willing to participate in the trial by signing an informed consent form.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1-BTA Lanzhou/Allergan (Type: ACTIVE_COMPARATOR): Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
- 2. BTA Allergan/Lanzhou (Type: ACTIVE_COMPARATOR): Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.

Based on this trial design, predict the completion outcome and termination type (if applicable).